Date: 2016-04-18
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at the Annual Meeting 2016 of the American Association for Cancer Research (AACR) in New Orleans
Company: Epigenomics (Germany - USA)
Product: panel of blood-based DNA methylation biomarkers
Action
mechanism: biomarker
Disease: lung cancer
Therapeutic area: Cancer - Oncology - Diagnostic
Country:
Trial details:
Latest
news: * On April 18, 2016, Epigenomics announced that the company will present data from a validation study with a proprietary panel of blood-based DNA methylation biomarkers for the detection of lung cancer at the Annual Meeting 2016 of the American Association for Cancer Research (AACR) in New Orleans, Louisiana. The poster titled “Classification of patients with lung cancer and benign lung disease via assessment of DNA methylation of SHOX2 and PTGER4 in plasma” will be presented by Dr. Gunter Weiss, Epigenomics’ Vice President Product Development,
(Abstract No: 2260 - Title: Biomarkers for Lung Cancer Authors: A. Schlegel, O. Hasinger, S. Esche, M. Martini, T. König, G. Weiss).
